Trial Profile
Phase II trial of telaprevir in patients with HCV who have CC genetic marker.
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2011
Price :
$35
*
At a glance
- Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 29 Jul 2011 Planned number of patients changed to approximately 400.
- 29 Jul 2011 Planned initiation date changed from 1 Jul 2011 to 1 Aug 2011.
- 17 May 2011 New trial record